Covid 19 Research using Clinical Trials (Home Page)
2: Standard of careWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
|
Name (Synonyms) |
Correlation |
drug18 | 1: Naproxen Wiki | 1.00 |
Correlated MeSH Terms (1)
|
Name (Synonyms) |
Correlation |
D016638 | Critical Illness NIH | 0.14 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
The symptoms of respiratory distress caused by COVID-19 may be reduced by drugs combining
anti-inflammatory and antiviral effects. This dual effect may simultaneously protect
severely-ill patients and reduce the viral load, therefore limiting virus dissemination We
want to demonstrate the superiority of naproxen (anti-inflamatory drug) treatment addition to
standard of care compared to standard of care in term of 30-day mortality.
NCT04325633 COVID-19 Drug: 1: Naproxen Drug: 2: Standard of care
Primary Outcomes
Measure: Mortality all causes at day30 Time: at day30
Secondary Outcomes
Measure: Number of days alive free of mechanical ventilation Time: during 30 days after randomization
Measure: Number of days alive outside Time: during 30 days after randomization
Measure: Number of days alive outside hospital Time: during 30 days after randomization
Measure: Maximal changes in Sofa score Time: in the first 7 days after randomization
Measure: Time to negativation of virus titer in the nasopharyngeal aspirate (NPA) Time: during 90 days after randomization
No related HPO nodes (Using clinical trials)